Fig. 4From: Sex hormones influence survival of patients with metastatic urothelial carcinoma undergoing immune checkpoint therapyChanges of hormone levels during therapy in females with first and second-line immunotherapy. Females receiving first-line immunotherapy showed decreasing LH levels, just missing statistical significance. First line (1L) pembrolizumab (n = 5), second line (2L) pembrolizumab (n = 5)Back to article page